LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Home・Akciju saraksts・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Slēgts

1.4 -2.1

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.4

Max

1.42

Galvenie mērījumi
By Trading Economics
Ienākumi	183K -27M
EPS	-0.37
Peļņas marža	-176.706
Darbinieki	166
EBITDA	9.4M -27M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+371.43% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	6.7M 102M
Iepriekšējā atvēršanas cena	3.5
Iepriekšējā slēgšanas cena	1.4

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

1.23 / 1.45 Atbalsts un pretestība

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 14. dec. 22:53 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

2025. g. 13. dec. 00:04 UTC

Iegādes, apvienošanās, pārņemšana

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

2025. g. 14. dec. 23:46 UTC

Tirgus saruna

Gold Edges Higher Amid Some Tailwinds -- Market Talk

2025. g. 14. dec. 23:36 UTC

Tirgus saruna

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

2025. g. 14. dec. 22:38 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue to Take Full Control of US$101M Copper Miner Alta

2025. g. 14. dec. 22:02 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

2025. g. 14. dec. 22:01 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue: Alta Owns the Canariaco Project in Northern Peru

2025. g. 14. dec. 22:01 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

2025. g. 14. dec. 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue: Agreement Implies Total Equity Value of C$139 Million

2025. g. 14. dec. 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

2025. g. 14. dec. 21:59 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue to Acquire Remaining 64% of Alta Copper

2025. g. 14. dec. 17:00 UTC

Peļņas

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

2025. g. 14. dec. 08:30 UTC

Iegādes, apvienošanās, pārņemšana

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

2025. g. 13. dec. 16:48 UTC

Iegādes, apvienošanās, pārņemšana

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

2025. g. 13. dec. 08:00 UTC

Iegādes, apvienošanās, pārņemšana

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

2025. g. 13. dec. 07:00 UTC

Iegādes, apvienošanās, pārņemšana

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

2025. g. 13. dec. 00:24 UTC

Iegādes, apvienošanās, pārņemšana

Want a Piece Of SpaceX? -- Barrons.com

2025. g. 12. dec. 23:49 UTC

Iegādes, apvienošanās, pārņemšana

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

2025. g. 12. dec. 22:52 UTC

Tirgus saruna

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

2025. g. 12. dec. 22:32 UTC

Peļņas

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

2025. g. 12. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 12. dec. 20:45 UTC

Peļņas

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

2025. g. 12. dec. 20:41 UTC

Tirgus saruna

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

2025. g. 12. dec. 20:20 UTC

Tirgus saruna

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

2025. g. 12. dec. 19:23 UTC

Peļņas

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

2025. g. 12. dec. 18:35 UTC

Iegādes, apvienošanās, pārņemšana

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

2025. g. 12. dec. 18:33 UTC

Iegādes, apvienošanās, pārņemšana

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

2025. g. 12. dec. 18:31 UTC

Tirgus saruna

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

2025. g. 12. dec. 17:49 UTC

Peļņas

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

2025. g. 12. dec. 17:34 UTC

Iegādes, apvienošanās, pārņemšana

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

371.43% augšup

Prognoze 12 mēnešiem

Vidējais 6.6 USD 371.43%

Augstākais 10 USD

Zemākais 4 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

1.23 / 1.45Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

There is one bearish event.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.